| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 149, 1707-1717, Copyright © 1996 by American Society for Investigative Pathology
REGULAR ARTICLES |
Y Yao, L Jin, A Fuchs, A Joseph, HM Hastings, ID Goldberg and EM Rosen
Department of Radiation Oncology, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA.
Scatter factor (SF) is an invasogenic and angiogenic cytokine the cellular receptor of which is encoded by a proto-oncogene (c-met). We measured the immunoreactive SF content (nanograms of SF per milligram of protein) in tissue extracts from 166 breast cancers and correlated the values with various known prognostic parameters. Invasive cancers had nearly four times greater SF content than did ductal carcinoma in situ, and the difference was statistically significant (P < 0.02, two- tailed t-test). However, there were no significant differences in SF content among different histological types of invasive cancer. Invasive cancers that had spread to axillary lymph nodes exhibited higher SF content than did invasive cancers without regional spread (P < 0.02), but the difference in SF content between node-positive and node- negative tumors was not as great as that between invasive and ductal carcinoma in situ tumors. There was a trend toward increased SF content in larger primary tumors as compared with smaller tumors, but statistical comparison revealed borderline significance (0.05 < P < 1.0). There was no significant correlation between SF content and other parameters, including estrogen receptor, progesterone receptor, DNA ploidy, S phase, or Scarff-Bloom-Richardson score. We also measured the content of von Willebrand factor (a marker of blood vessels) and interleukin-1 beta (a pro-inflammatory cytokine) in the same tumor extracts. SF content showed a strong positive correlation with von Willebrand factor content (P < 0.001) but did not appear to be correlated with interleukin-1 beta. These findings suggest that SF is correlated with several other clinicopathological indicators of aggressive tumor behavior, consistent with the hypothesis that SF is a biological factor that may play a role in breast cancer pathogenesis.
This article has been cited by other articles:
 |
|
 |
|
  D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells Cancer Res., March 1, 2008; 68(5): 1471 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Shattuck, J. K. Miller, M. Laederich, M. Funes, H. Petersen, K. L. Carraway III, and C. Sweeney LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 Synergy Mol. Cell. Biol., March 1, 2007; 27(5): 1934 - 1946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tacchini, C. De Ponti, E. Matteucci, R. Follis, and M.A. Desiderio Hepatocyte growth factor-activated NF-{kappa}B regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines Carcinogenesis, November 1, 2004; 25(11): 2089 - 2100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Wright, J. Tsai, Z. Jia, and B. E. Elliott Inhibition by Copper(II) Binding of Hepatocyte Growth Factor (HGF) Interaction with Its Receptor Met and Blockade of HGF/Met Function J. Biol. Chem., July 30, 2004; 279(31): 32499 - 32506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Parr, G. Watkins, R. E. Mansel, and W. G. Jiang The Hepatocyte Growth Factor Regulatory Factors in Human Breast Cancer Clin. Cancer Res., January 1, 2004; 10(1): 202 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Martin, C. Parr, G. Davies, G. Watkins, J. Lane, K. Matsumoto, T. Nakamura, R. E. Mansel, and W. G. Jiang Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist Carcinogenesis, August 1, 2003; 24(8): 1317 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Kang, M. Dolled-Filhart, I. T. Ocal, B. Singh, C.-Y. Lin, R. B. Dickson, D. L. Rimm, and R. L. Camp Tissue Microarray Analysis of Hepatocyte Growth Factor/Met Pathway Components Reveals a Role for Met, Matriptase, and Hepatocyte Growth Factor Activator Inhibitor 1 in the Progression of Node-negative Breast Cancer Cancer Res., March 1, 2003; 63(5): 1101 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Peghini, M. Iwamoto, M. Raffeld, Y.-J. Chen, S. U. Goebel, J. Serrano, and R. T. Jensen Overexpression of Epidermal Growth Factor and Hepatocyte Growth Factor Receptors in a Proportion of Gastrinomas Correlates with Aggressive Growth and Lower Curability Clin. Cancer Res., July 1, 2002; 8(7): 2273 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gao, S. Fan, I. D. Goldberg, J. Laterra, R. N. Kitsis, and E. M. Rosen Hepatocyte Growth Factor/Scatter Factor Blocks the Mitochondrial Pathway of Apoptosis Signaling in Breast Cancer Cells J. Biol. Chem., December 7, 2001; 276(50): 47257 - 47265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Jiang, D. Grimshaw, J. Lane, T. A. Martin, R. Abounder, J. Laterra, and R. E. Mansel A Hammerhead Ribozyme Suppresses Expression of Hepatocyte Growth Factor/Scatter Factor Receptor c-MET and Reduces Migration and Invasiveness of Breast Cancer Cells Clin. Cancer Res., August 1, 2001; 7(8): 2555 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Siegfried, L. A. Weissfeld, J. D. Luketich, R. J. Weyant, C. T. Gubish, and R. J. Landreneau The clinical significance of hepatocyte growth factor for non-small cell lung cancer Ann. Thorac. Surg., December 1, 1998; 66(6): 1915 - 1918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lail-Trecker, R. Gulati, and J. J. Peluso A Role for Hepatocyte Growth Factors/Scatter Factor in Regulating Normal and Neoplastic Cells of Reproductive Tissues Reproductive Sciences, May 1, 1998; 5(3): 114 - 121. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
